News | Clinical Decision Support | April 29, 2015

Gregg W. Stone Appointed to COR Medical Technologies' Senior Editorial Board

Columbia University Medical center physician, professor brings cardiovascular expertise to review of current medical research, conditions and treatments

April 29, 2015 — COR Medical Technologies (COR) announced that Gregg W. Stone, M.D. has been appointed to its Senior Editorial Board. 

Stone is a professor of medicine at Columbia University and the director of cardiovascular research and education for the Center for Interventional Vascular Therapy at the Columbia University Medical Center and New York Presbyterian Hospital in New York City. Stone also serves as the co-director of medical research and education at the Cardiovascular Research Foundation in New York. 

COR’s Senior Editorial Board provides input on current medical research, conditions and treatments. The board reviews conditions and best practice treatments in order to provide instant decision support from the most current, vetted information available to treat cardiovascular conditions.

“We are pleased to have Dr. Stone join the COR Senior Editorial Board,” said Vince Friedewald, M.D., COR founder and CEO.  “His cardiovascular and interventional vascular therapy experience adds great value to our team.”

Stone received his medical degree from the John Hopkins School of Medicine in Baltimore and completed his residency in internal medicine at the New York Hospital – Cornell Medical Center in New York City.  He trained in cardiology at Cedars-Sinai Medical Center in Los Angeles, and in advanced angioplasty at the Mid-America Heart Institute in Kansas City, Missouri. He is board certified by the American Board of Interventional Cardiology, American Board of Cardiovascular Diseases and American Board of Internal Medicine.

“I am honored to join the distinguished group of medical experts who sit on the COR Medical Technologies Senior Editorial Board,” said Stone. “I am excited to share my experience in cardiovascular medicine with the other members.”

COR Medical Technologies offers CORcare, a comprehensive instant decision support system for rapid and accurate diagnosis, treatment and follow-up management of patients with acute and chronic, common and rare diseases involving the cardiovascular system.

For more information:

Related Content

Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab | November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab | November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Culprit Lesion-Only PCI Improves Outcomes for Cardiogenic Shock Patients Compared to Multivessel PCI
News | Cath Lab | November 01, 2017
November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strateg
Overlay Init